Samsung Biologics earnings increased in the third quarter of 2026, although operating profit grew much more slowly than revenue as the company expanded its manufacturing network. In its October 21 announcement, the South Korean contract drug manufacturer raised its full-year revenue growth guidance to 20% from a previous range of 15%–20%.
Key Takeaways
- Third-quarter revenue rose 18.5% year over year, while operating profit increased about 1.0%.
- Plant 5 and the acquired Rockville facility added revenue alongside fully utilized Plants 1 through 4.
- A planned KRW 3 trillion rights offering will help fund acquisitions and manufacturing expansion.
Table of Contents
- Samsung Biologics earnings lag revenue growth
- New manufacturing sites broaden revenue sources
- Higher guidance accompanies acquisition funding plans
- Conclusion
Samsung Biologics earnings lag revenue growth
Samsung Biologics’ third-quarter financial results showed revenue increasing by KRW 232.8 billion from a year earlier, compared with a KRW 6.6 billion increase in operating profit. The figures cover the company’s consolidated contract development and manufacturing business.
That difference reduced the operating profit margin to approximately 43.0%, from 50.4% in the third quarter of 2025. The release did not provide a detailed breakdown explaining the margin change.
| Item | Details |
|---|---|
| Revenue | Q3 2026: KRW 1,490.3 billion; Q3 2025: KRW 1,257.5 billion. |
| Operating profit | Q3 2026: KRW 640.1 billion; Q3 2025: KRW 633.5 billion. |
| EBITDA | Q3 2026: KRW 751.5 billion; Q3 2025: KRW 728.9 billion. |
New manufacturing sites broaden revenue sources
Plants 1 through 4 operated at full capacity, while Plant 5 made an increasing contribution as production ramped up. The Rockville manufacturing facility in Maryland also recorded its first revenue contribution since its acquisition.
Samsung Biologics said it maintained stable operations and workforce capabilities at Rockville while evaluating ways to adapt the facility to a broader range of client requirements. Together with its Songdo operations, the site gives the company manufacturing capacity in both South Korea and the United States.
Cumulative contract orders exceeded US$21.9 billion. That figure represents accumulated orders, not revenue earned during the quarter. The company also opened a sales office in the Netherlands to strengthen engagement with European pharmaceutical and biotechnology customers.
Higher guidance accompanies acquisition funding plans
The revised 20% annual revenue growth forecast places management’s expectation at the top of its former range. It remains guidance for 2026 rather than a completed full-year result.
Samsung Biologics is also pursuing its planned acquisition of PolyPeptide Group. Interim tender-offer results published in October showed an 87.92% participation rate, meeting the offer’s acceptance condition. The company did not describe the acquisition as completed.
The planned transaction would add peptide-based therapeutics services to Samsung Biologics’ existing antibody and conjugate capabilities, alongside PolyPeptide’s operations in Europe, the United States and India.
To support that acquisition and future manufacturing capacity expansion, Samsung Biologics announced a KRW 3 trillion rights offering. Existing shareholders are scheduled to subscribe in November 2026, with any unsubscribed shares subsequently offered to the general public.
Conclusion
Revenue growth and additional manufacturing contributions supported the higher annual outlook, while operating profit growth remained modest. The next scheduled financing milestone is the November shareholder subscription period for the rights offering.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
